Evaluation of Predictive Values of Naples Prognostic Score in Patients with Unresectable Stage III Non-Small Cell Lung Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Kishida Y, Hirose T, Shirai T, et al. Myelosuppression induced by concurrent chemoradiotherapy as a prognostic factor for patients with locally advanced non-small cell lung cancer. Oncol Lett. 2011;2(5):949–955. doi:10.3892/ol.2011.348
   PubMed Web of Science ®Google Scholar
• Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized Phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452–1460. doi:10.1093/jnci/djr325
   PubMedGoogle Scholar
• Feng W, Fu XL, Cai XW, et al. Patterns of local-regional failure in completely resected stage IIIA(N2) non-small cell lung cancer cases: implications for postoperative radiation therapy clinical target volume design. Int J Radiat Oncol Biol Phys. 2014;88(5):1100–1107. doi:10.1016/j.ijrobp.2013.12.048
   PubMed Web of Science ®Google Scholar
• Kong FM, Ten HRK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63(2):324–333. doi:10.1016/j.ijrobp.2005.02.010
   PubMed Web of Science ®Google Scholar
• Machtay M, Bae K, Movsas B, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012;82(1):425–434. doi:10.1016/j.ijrobp.2010.09.004
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–714. doi:10.1097/JTO.0b013e31812f3c1a
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg. 2012;36(3):617–622. doi:10.1007/s00268-011-1411-1
   PubMed Web of Science ®Google Scholar
• Yang L, Karin M. Roles of tumor suppressors in regulating tumor-associated inflammation. Cell Death Differ. 2014;21(11):1677–1686. doi:10.1038/cdd.2014.131
   PubMed Web of Science ®Google Scholar
• Guo D, Jin F, Jing W, et al. Incorporation of the SUVmax measured from FDG PET and neutrophil-to-lymphocyte ratio improves prediction of clinical outcomes in patients with locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2019;20(6):412–419. doi:10.1016/j.cllc.2019.06.008
   PubMed Web of Science ®Google Scholar
• Zhang N, Jiang J, Tang S, Sun G. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Int Immunopharmacol. 2020;85:106677. doi:10.1016/j.intimp.2020.106677
   PubMed Web of Science ®Google Scholar
• Guo D, Zhang J, Jing W, et al. Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. Future Oncol. 2018;14(25):2643–2650. doi:10.2217/fon-2018-0285
   PubMed Web of Science ®Google Scholar
• Hua X, Long ZQ, Huang X, et al. The value of Prognostic Nutritional Index (PNI) in predicting survival and guiding radiotherapy of patients with T1-2N1 breast cancer. Front Oncol. 2019;9:1562. doi:10.3389/fonc.2019.01562
   PubMed Web of Science ®Google Scholar
• Yang C, Wei C, Wang S, et al. Combined features based on preoperative controlling nutritional status score and circulating tumour cell status predict prognosis for colorectal cancer patients treated with curative resection. Int J Biol Sci. 2019;15(6):1325–1335. doi:10.7150/ijbs.33671
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Okabayashi K, Hasegawa H, et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer. Ann Surg. 2018;267(3):527–531. doi:10.1097/SLA.0000000000002115
   PubMed Web of Science ®Google Scholar
• Li Q, Cong R, Wang Y, et al. Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer: results from a retrospective cohort study. Gynecol Oncol. 2021;160(1):91–98. doi:10.1016/j.ygyno.2020.10.013
   PubMed Web of Science ®Google Scholar
• Galizia G, Lieto E, Auricchio A, et al. Naples Prognostic score, based on nutritional and inflammatory status, is an independent predictor of long-term outcome in patients undergoing surgery for colorectal cancer. Dis Colon Rectum. 2017;60(12):1273–1284. doi:10.1097/DCR.0000000000000961
   PubMed Web of Science ®Google Scholar
• Feng JF, Zhao JM, Chen S, Chen QX. Naples prognostic score: a novel prognostic score in predicting cancer-specific survival in patients with resected esophageal squamous cell carcinoma. Front Oncol. 2021;11:652537. doi:10.3389/fonc.2021.652537
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Hiyoshi Y, Daitoku N, et al. Naples prognostic score is a useful prognostic marker in patients with metastatic colorectal cancer. Dis Colon Rectum. 2019;62(12):1485–1493. doi:10.1097/DCR.0000000000001484
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0
   PubMed Web of Science ®Google Scholar
• Zhu H, Cao X. NLR members in inflammation-associated carcinogenesis. Cell Mol Immunol. 2017;14(5):403–405. doi:10.1038/cmi.2017.14
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015;36(10):1085–1093. doi:10.1093/carcin/bgv123
   PubMed Web of Science ®Google Scholar
• Takahashi R, Mabuchi S, Kuroda H, et al. The SIGNIFICANCE of pretreatment thrombocytosis and its association with neutrophilia in patients with surgically treated endometrial cancer. Int J Gynecol Cancer. 2017;27(7):1399–1407. doi:10.1097/IGC.0000000000001019
   PubMed Web of Science ®Google Scholar
• Schernberg A, Nivet A, Dhermain F, et al. Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation. Clin Transl Radiat Oncol. 2018;10:47–52. doi:10.1016/j.ctro.2018.04.002
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–5391. doi:10.1158/0008-5472.CAN-08-3845
   PubMed Web of Science ®Google Scholar
• Tang C, Liao Z, Gomez D, et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014;89(5):1084–1091. doi:10.1016/j.ijrobp.2014.04.025
   PubMed Web of Science ®Google Scholar
• Menetrier-Caux C, Ray-Coquard I, Blay JY, Caux C. Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immunother Cancer. 2019;7(1):85. doi:10.1186/s40425-019-0549-5
   PubMedGoogle Scholar
• Kitamura T, Doughty-Shenton D, Cassetta L, et al. Monocytes differentiate to immune suppressive precursors of metastasis-associated macrophages in mouse models of metastatic breast cancer. Front Immunol. 2017;8:2004. doi:10.3389/fimmu.2017.02004
   PubMed Web of Science ®Google Scholar
• Parikh K, Kumar A, Ahmed J, et al. Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer. Cancer Immunol Immunother. 2018;67(9):1365–1370. doi:10.1007/s00262-018-2192-2
   PubMed Web of Science ®Google Scholar
• Houghton AM, Rzymkiewicz DM, Ji H, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010;16(2):219–223. doi:10.1038/nm.2084
   PubMed Web of Science ®Google Scholar
• Wu L, Saxena S, Awaji M, Singh RK. Tumor-associated neutrophils in cancer: going pro. Cancers (Basel). 2019;11:4. doi:10.3390/cancers11040564
   Google Scholar
• Droin N, Hendra JB, Ducoroy P, Solary E. Human defensins as cancer biomarkers and antitumour molecules. J Proteomics. 2009;72(6):918–927. doi:10.1016/j.jprot.2009.01.002
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107–1111. doi:10.1038/35074122
   PubMed Web of Science ®Google Scholar
• Laviron M, Combadiere C, Boissonnas A. Tracking monocytes and macrophages in tumors with live imaging. Front Immunol. 2019;10:1201. doi:10.3389/fimmu.2019.01201
   PubMed Web of Science ®Google Scholar
• Bun A, Fujimoto Y, Higuchi T, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in luminal breast cancers with low levels of tumour-infiltrating lymphocytes. Anticancer Res. 2020;40(5):2871–2880. doi:10.21873/anticanres.14263
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi:10.1093/jnci/dju124
   PubMedGoogle Scholar
• Zhao QT, Yang Y, Xu S, et al. Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7054 patients. Onco Targets Ther. 2015;8:2731–2738. doi:10.2147/OTT.S90875
   PubMed Web of Science ®Google Scholar
• Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):971–978. doi:10.1016/j.ctrv.2015.10.003
   PubMed Web of Science ®Google Scholar
• Yan H, Cai L, Chen S, Li J. Preoperative lymphocyte-to-monocyte ratio versus platelet-to-lymphocyte ratio as a prognostic predictor for non-small cell lung cancer patients. J Med Biochem. 2020;39(2):160–164. doi:10.2478/jomb-2019-0031
   PubMed Web of Science ®Google Scholar
• Tokunaga R, Sakamoto Y, Nakagawa S, et al. CONUT: a novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. Int J Colorectal Dis. 2017;32(1):99–106. doi:10.1007/s00384-016-2668-5
   PubMed Web of Science ®Google Scholar
• Morhij R, Mahendra A, Jane M, McMillan DC. The modified Glasgow prognostic score in patients undergoing surgery for bone and soft tissue sarcoma. J Plast Reconstr Aesthet Surg. 2017;70(5):618–624. doi:10.1016/j.bjps.2017.01.016
   PubMed Web of Science ®Google Scholar
• Sun H, Yuan Y, Wang P, et al. Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis. Lipids Health Dis. 2015;14:140. doi:10.1186/s12944-015-0147-6
   PubMed Web of Science ®Google Scholar
• Tanne JH. Meta-analysis says low LDL cholesterol may be associated with greater risk of cancer. BMJ. 2007;335(7612):177. doi:10.1136/bmj.39287.415347.DB
   PubMedGoogle Scholar
• Tomita M, Ayabe T, Shimizu T, Nakamura K. Preoperative total serum cholesterol and patients’ survival in resected nonsmall cell lung cancer. Lung Cancer Int. 2012;2012:463520. doi:10.1155/2012/463520
   PubMedGoogle Scholar
• Mandal CC, Rahman MM. Targeting intracellular cholesterol is a novel therapeutic strategy for cancer treatment. J Cancer Sci Ther. 2014;6(12):510–513. doi:10.4172/1948-5956.1000316
   PubMedGoogle Scholar
• Oliver MF. Serum cholesterol–the knave of hearts and the joker. Lancet. 1981;2(8255):1090–1095. doi:10.1016/S0140-6736(81)91286-1
   PubMed Web of Science ®Google Scholar
• Nakagawa N, Yamada S, Sonohara F, et al. Clinical implications of Naples prognostic score in patients with resected pancreatic cancer. Ann Surg Oncol. 2020;27(3):887–895. doi:10.1245/s10434-019-08047-7
   PubMed Web of Science ®Google Scholar
• Kano K, Yamada T, Yamamoto K, et al. The impact of pretherapeutic Naples prognostic score on survival in patients with locally advanced esophageal cancer. Ann Surg Oncol. 2021;28(8):4530–4539. doi:10.1245/s10434-020-09549-5
   PubMed Web of Science ®Google Scholar
• Li S, Wang H, Yang Z, et al. Naples Prognostic Score as a novel prognostic prediction tool in video-assisted thoracoscopic surgery for early-stage lung cancer: a propensity score matching study. Surg Endosc. 2021;35(7):3679–3697. doi:10.1007/s00464-020-07851-7
   PubMed Web of Science ®Google Scholar